DAVID L contact RIMM

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
    Yasmine Nadler
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Breast Cancer Res 10:R35. 2008
  2. ncbi Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues
    Veronique M Neumeister
    Department of Pathology, BML Rm 116, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 8023, USA
    J Natl Cancer Inst 104:1815-24. 2012
  3. ncbi C-path: a Watson-like visit to the pathology lab
    David L Rimm
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    Sci Transl Med 3:108fs8. 2011
  4. ncbi Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
    Maria T Baquero
    Yale University School of Medicine, Department of Pathology, 310 Cedar St, New Haven, CT 06520, USA
    Breast Cancer Res 13:R85. 2011
  5. ncbi The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
    Jerzy Rokicki
    Department of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana 70118, USA
    Mol Cancer 9:150. 2010
  6. ncbi The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    J Transl Med 5:6. 2007
  7. ncbi Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma
    Juliana Tolles
    Division of Biostatistics, Yale University School of Public Health, New Haven, CT 06511, USA
    Breast Cancer Res 13:R51. 2011
  8. ncbi Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry
    Summar Siddiqui
    Department of Pathology, Yale University School of Medicine, BML 116, 310 Cedar Street, P, O, Box 208023, New Haven, CT 06520 8023, USA
    Breast Cancer Res 12:113. 2010
  9. ncbi Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
    Susan A Higgins
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA
    Breast Cancer Res 7:R1017-22. 2005
  10. ncbi Utility of multispectral imaging for nuclear classification of routine clinical histopathology imagery
    Laura E Boucheron
    Electrical and Computer Engineering Department, University of California, Santa Barbara, CA 93106, USA
    BMC Cell Biol 8:S8. 2007

Research Grants

  1. Optimal Predictors of Response to Trastuzumab
    DAVID L contact RIMM; Fiscal Year: 2010
  2. Predicting Metastasis in Melanoma
    David Rimm; Fiscal Year: 2009
  3. Prediction of Breast Cancer Response to Hormonal Thearpy
    David Rimm; Fiscal Year: 2007
  4. Predicting Metastasis to Lymph Nodes
    David Rimm; Fiscal Year: 2007
  5. Predicting Metastasis in Melanoma
    David Rimm; Fiscal Year: 2007
  6. AQUA: A New Quantitative in situ Proteomic Assay
    David Rimm; Fiscal Year: 2004
  7. ESTABLISHMENT AND REGULATION OF CELL/CELL ADHESION
    David Rimm; Fiscal Year: 2002
  8. Predicting Metastasis in Melanoma
    David L Rimm; Fiscal Year: 2010

Detail Information

Publications95

  1. ncbi Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
    Yasmine Nadler
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Breast Cancer Res 10:R35. 2008
    ....
  2. ncbi Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues
    Veronique M Neumeister
    Department of Pathology, BML Rm 116, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06520 8023, USA
    J Natl Cancer Inst 104:1815-24. 2012
    ..We examined 23 proteins, including four commonly used breast cancer biomarker proteins, to quantify their sensitivity to cold ischemia in breast cancer tissues...
  3. ncbi C-path: a Watson-like visit to the pathology lab
    David L Rimm
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    Sci Transl Med 3:108fs8. 2011
    ..Computer-based quantification of tumor morphology has arguably solved the problem of standardized tumor grading (Beck et al., this issue)...
  4. ncbi Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
    Maria T Baquero
    Yale University School of Medicine, Department of Pathology, 310 Cedar St, New Haven, CT 06520, USA
    Breast Cancer Res 13:R85. 2011
    ..The microtubule stabilizer, MAP-tau, has shown conflicting results. We quantitatively assessed MAP-tau expression in two independent breast cancer cohorts to determine prognostic and predictive value of this biomarker...
  5. ncbi The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
    Jerzy Rokicki
    Department of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana 70118, USA
    Mol Cancer 9:150. 2010
    ..We propose that direct coupling of these signaling pathways may have important implications for mammary development, breast carcinogenesis, and patient response to endocrine therapy...
  6. ncbi The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    J Transl Med 5:6. 2007
    ..Targeting XIAP warrants additional investigation as a therapeutic approach for metastatic melanoma...
  7. ncbi Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma
    Juliana Tolles
    Division of Biostatistics, Yale University School of Public Health, New Haven, CT 06511, USA
    Breast Cancer Res 13:R51. 2011
    ....
  8. ncbi Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry
    Summar Siddiqui
    Department of Pathology, Yale University School of Medicine, BML 116, 310 Cedar Street, P, O, Box 208023, New Haven, CT 06520 8023, USA
    Breast Cancer Res 12:113. 2010
    ..As a result, it is likely that future companion diagnostic tests that include phospho-specific epitopes will be reliably done only in core needle biopsies that minimize ischemic time...
  9. ncbi Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
    Susan A Higgins
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA
    Breast Cancer Res 7:R1017-22. 2005
    ..However, we observed a significantly lower proportion of fluid-yielding subjects in a similar series of high-risk women. The purpose of the present study was to identify variables associated with this reduction...
  10. ncbi Utility of multispectral imaging for nuclear classification of routine clinical histopathology imagery
    Laura E Boucheron
    Electrical and Computer Engineering Department, University of California, Santa Barbara, CA 93106, USA
    BMC Cell Biol 8:S8. 2007
    ..It has been hypothesized that the additional spectral bands contain further information useful for classification as compared to the 3 standard bands of RGB imagery. We present analyses of our data designed to test this hypothesis...
  11. ncbi High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:186. 2010
    ..Bcl-2 has been investigated as a prognostic factor in non small cell lung cancer (NSCLC) patients with conflicting results...
  12. ncbi Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues
    David L Rimm
    Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 29:2282-90. 2011
    ..We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population...
  13. ncbi What brown cannot do for you
    David L Rimm
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520-8023, USA
    Nat Biotechnol 24:914-6. 2006
  14. ncbi Amplification of tissue by construction of tissue microarrays
    D L Rimm
    Department of Pathology and the Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Exp Mol Pathol 70:255-64. 2001
    ..It has the potential for allowing validation of new genes at a speed comparable to the rapid rate of gene discovery afforded by DNA microarrays...
  15. ncbi Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma
    D L Rimm
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Am J Pathol 154:325-9. 1999
    ....
  16. ncbi Degree of dysplasia following diagnosis of atypical squamous cells of undetermined significance is influenced by patient history and type of follow-up
    R A Ghoussoub
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Diagn Cytopathol 17:14-9. 1997
    ..in the process of defining the clinical and biological implications of the ASCUS diagnosis...
  17. ncbi Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors
    Idris Tolgay Ocal
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer 97:1841-8. 2003
    ..Furthermore, this group of patients is associated tightly and independently with worse outcome...
  18. ncbi Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 15:1179-83. 2006
    ..Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  19. ncbi Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray
    Doo Ho Choi
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer J 11:404-11. 2005
    ..Further studies are needed to find other biologic markers associated with local failure in this group of patients...
  20. ncbi Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
    Janice M Mehnert
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 41:375-84. 2010
    ..Such assessments could assist with evaluation of these molecules as therapeutic targets in melanoma, ultimately facilitating improved selection of patients for treatment...
  21. ncbi Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Natl Cancer Inst 101:452-74. 2009
    ....
  22. ncbi High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
    Sriparna Ghosh
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 39:1835-43. 2008
    ..Further study of the functional significance of this finding is warranted as well as the prognostic value of these biomarkers in other tumor microenvironment-specific compartments (eg, vessels)...
  23. ncbi Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer
    Jennifer M Giltnane
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 25:3007-14. 2007
    ..Here we assess the relationship between EGFR expression and tamoxifen response, with a new quantitative technology...
  24. ncbi Gab2-mediated signaling promotes melanoma metastasis
    Basil Horst
    Columbia University, Department of Pathology, New York, NY 10032, USA
    Am J Pathol 174:1524-33. 2009
    ..Gab2 overexpression resulted in enhanced tumor growth and metastatic potential in vivo. These studies demonstrate a previously undefined role for Gab2 in melanoma tumor progression and metastasis...
  25. ncbi Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis
    Anthony McCabe
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA
    J Natl Cancer Inst 97:1808-15. 2005
    ..47, 95% CI = 0.29 to 0.76; P = .002), compared with low HER2 expression. CONCLUSIONS: Biomarker antibody concentration appears to dramatically affect the apparent relationship between biomarker expression and outcome...
  26. ncbi Classification of breast cancer using genetic algorithms and tissue microarrays
    Marisa Dolled-Filhart
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA
    Clin Cancer Res 12:6459-68. 2006
    ..More generally, this work illustrates the potential for multiplexed biomarker discovery on the tissue microarray platform...
  27. ncbi Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma
    Ziwei Yu
    Department of Otolaryngology, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Cancer Res 11:1160-6. 2005
    ..In this study, we sought to determine the prognostic significance of the cell cycle regulator cyclin D1 in oropharyngeal squamous cell carcinoma (OSCC)...
  28. ncbi Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort
    Jennifer M Giltnane
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Cancer 115:2400-9. 2009
    ..The authors hypothesized that multiplexed quantitative measurement of ErbB receptor family proteins may allow better prediction of outcome...
  29. ncbi Melanoma prognostic model using tissue microarrays and genetic algorithms
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:5772-80. 2009
    ..Here, we propose a multimarker molecular prognostic assay that can help triage patients at increased risk of recurrence...
  30. ncbi High HSP90 expression is associated with decreased survival in breast cancer
    Elah Pick
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 67:2932-7. 2007
    ..Prospective studies are needed to confirm the prognostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors...
  31. ncbi High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Clin Cancer Res 15:4157-64. 2009
    ..Here, we quantitatively assessed mTOR protein expression in two large data sets to investigate the impact of mTOR expression on patient survival...
  32. ncbi Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:271-8. 2009
    ..We quantitatively assessed TTF1 protein expression in two large and independent data sets to investigate the impact of TTF1 nuclear expression on patient survival...
  33. ncbi Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer Res 63:8103-7. 2003
    ..Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage melanoma...
  34. ncbi Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implicatio
    Christopher B Moeder
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 25:5418-25. 2007
    ..6-mm spot is equivalent to two to three high-power fields, we used TMAs to assess levels of heterogeneity and to determine optimal representation as a function of outcome...
  35. ncbi Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome
    Malini Harigopal
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Am J Pathol 176:1639-47. 2010
    ..This assay method may provide a new companion diagnostic approach for targeted therapies...
  36. ncbi Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
    Keith Hoek
    Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520-8059, USA
    Cancer Res 64:5270-82. 2004
    ..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients...
  37. ncbi Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Arch Pathol Lab Med 134:613-9. 2010
    ..6-mm to 1.5-mm core "biopsies" of standard formalin-fixed, paraffin-embedded tissue blocks and by the processing of hundreds of cases arrayed on a single recipient block in an identical manner...
  38. ncbi Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 65:5578-87. 2005
    ....
  39. ncbi Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome
    Eric Kielhorn
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA
    Int J Cancer 103:652-6. 2003
    ..046). These results suggest that phospho-specific antibodies to beta-catenin define a unique subset of cases and that monitoring of phospho-beta-catenin expression may be useful for assessing prognosis in malignant melanoma...
  40. ncbi The histologic subtype of ovarian tumors affects the detection rate by pelvic washings
    Oluwole Fadare
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 102:150-6. 2004
    ..The histologic subtype of the underlying ovarian tumor was found to have an effect on the likelihood of detection of peritoneal involvement using this diagnostic assay...
  41. ncbi Automated analysis of tissue microarrays
    Marisa Dolled-Filhart
    HistoRx, Inc, New Haven, CT, USA
    Methods Mol Biol 664:151-62. 2010
    ..Ultimately this allows for a multiplexed, objective and standardized quantitative approach for biomarker research and diagnostic assay development for protein expression in tissue...
  42. ncbi Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Mod Pathol 21:1121-9. 2008
    ..80 for distinguishing benign nevi from malignant melanomas. On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions...
  43. ncbi Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma
    Kyle A Divito
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8773-7. 2004
    ..These results suggest studies are needed to evaluate the association between quantitative assessment of Bcl-2 expression and response to Bcl-2 targeting therapy toward the goal of improved response rates to these drugs...
  44. ncbi Analytic variability in immunohistochemistry biomarker studies
    Valsamo K Anagnostou
    Department of Pathology, Yale Cancer Center, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 19:982-91. 2010
    ..Here we describe the effect of variable antibody reagents in the assessment of cancer-related biomarkers by IHC...
  45. ncbi p53 mutations as tumor markers in fine needle aspirates of palpable breast masses
    Deborah A Dillon
    Department of Pathology LH219, Yale University School of Medicine, P O Box 208023, New Haven, Connecticut 06520 8023, USA
    Acta Cytol 46:841-7. 2002
    ..We performed a retrospective analysis of p53 mutations in fluid-based, archival fine needle aspirates (FNAs) of breast masses to determine their potential diagnostic utility as breast tumor cell markers...
  46. ncbi Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 63:1445-8. 2003
    ..Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome...
  47. ncbi Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis
    Harriet M Kluger
    Departments of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 10:173-7. 2004
    ..Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data...
  48. ncbi Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose
    Eitan M Akirav
    Department of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Diabetes 60:876-83. 2011
    ..Our objective was to study the effects of glucose and inflammation on islet vascularity and on β function, mass, and insulin in immunologically tolerant anti-CD3 monoclonal antibody (mAb)-treated and prediabetic NOD mice...
  49. ncbi Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome
    Malini Harigopal
    Yale University School of Medicine, New Haven, CT 06510, USA
    Breast Cancer Res Treat 115:77-85. 2009
    ....
  50. ncbi Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer
    Yasmine Nadler
    Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 14:4455-62. 2008
    ..We therefore assessed expression of Aurora A and B in breast tumors and studied associations with clinical/pathologic variables...
  51. ncbi Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer
    Jennifer M Giltnane
    Departments of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Arch Pathol Lab Med 132:1635-47. 2008
    ..Although many studies have compared IHC to FISH, few have compared the tests to the true gold standard, tumor response...
  52. ncbi Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization
    Bonnie L King
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 9:1509-16. 2003
    ..The purpose of our study was to evaluate the correlation between cancer-associated abnormalities in breast lesions and exfoliated breast cells collected by ductal lavage...
  53. ncbi Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis
    Marisa Dolled-Filhart
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 9:594-600. 2003
    ....
  54. ncbi Immunocytochemical analysis of breast cells obtained by ductal lavage
    Bonnie L King
    Department of Therapeutic Radiology, Yale University School of Medicine, Hunter Radiation Therapy, New Haven, Connecticut 06520, USA
    Cancer 96:244-9. 2002
    ..In the current study, the authors performed immunocytochemical analysis with epithelial specific and macrophage specific antibodies to characterize and quantify breast cells obtained by ductal lavage...
  55. ncbi beta-Catenin and p53 analyses of a breast carcinoma tissue microarray
    Gina G Chung
    Section of Medical Oncology, Yale Cancer Center, New Haven, Connecticut 06520, USA
    Cancer 100:2084-92. 2004
    ..Recently, it was shown that p53 down-regulated beta-catenin in a complex fashion. The authors examined the expression of beta-catenin, key members of its signaling pathway, and p53 in a large cohort of breast tumors...
  56. ncbi Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Melanoma Res 14:207-10. 2004
    ..Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence...
  57. ncbi Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 11:8637-43. 2005
    ..Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  58. ncbi Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 11:8384-90. 2005
    ..However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  59. ncbi Cruella: developing a scalable tissue microarray data management system
    James D Cowan
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Arch Pathol Lab Med 130:817-22. 2006
    ..These issues include the requirement to accommodate new and different data elements for each new project as well as the need to interact with pre-existing models for clinical, biological, and specimen-related data...
  60. ncbi Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray
    Gina G Chung
    Yale Cancer Center and Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer 106:1677-84. 2006
    ....
  61. ncbi Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer
    Malini Harigopal
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:4083-9. 2005
    ..We investigated the relationship between E-cadherin expression in primary invasive ductal tumors and corresponding nodal metastases, and determined the prognostic value of E-cadherin expression in node-positive breast cancer...
  62. ncbi Quantitative analysis of estrogen receptor heterogeneity in breast cancer
    Gina G Chung
    Medical Oncology, Yale Cancer Center, New Haven, CT 06520, USA
    Lab Invest 87:662-9. 2007
    ..It is also likely to be dependent on the biomarker analyzed and suggests further studies should be carried out to determine how these findings may affect clinical decision-making processes...
  63. ncbi Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer
    Oluwole Fadare
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06504, USA
    Mod Pathol 18:673-80. 2005
    ..5%), but does not appear to affect their overall outcome. Although this is a small single site study, it raises questions about the value of this procedure in patients with endometrial cancer...
  64. ncbi Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8767-72. 2004
    ....
  65. ncbi X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 10:7252-9. 2004
    ....
  66. ncbi Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Invest Dermatol 130:1971-87. 2010
    ..These identified 101 additional proteins that stratify melanoma, organized according to the Hanahan and Weinberg functional capabilities of cancer...
  67. ncbi Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:5188-94. 2005
    ..We sought to determine the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in early-stage breast cancer...
  68. ncbi Phosphatidylinositol-3-kinase as a therapeutic target in melanoma
    Saadia A Aziz
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 15:3029-36. 2009
    ..We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002...
  69. ncbi PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer
    Joshua VanHouten
    Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 107:11405-10. 2010
    ..We conclude that loss of PMCA2 expression at weaning triggers apoptosis by causing cellular calcium crisis. PMCA2 overexpression, on the other hand, may play a role in breast cancer progression by conferring resistance to apoptosis...
  70. ncbi Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome
    Summar F Siddiqui
    Department of Pathology, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520-8023, USA
    Cancer Epidemiol Biomarkers Prev 14:2517-23. 2005
    ..Our results indicate that GnT-V substrate proteins represent a unique subset of coexpressed tumor markers associated with aggressive disease...
  71. ncbi A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers
    Robert L Camp
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520 8023, USA
    J Clin Oncol 26:5630-7. 2008
    ..We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy...
  72. ncbi Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer
    C A W Sullivan
    Yale University School of Medicine, Yale Cancer Center, Section of Medical Oncology, 333 Cedar St, New Haven, CT 06520, USA
    Hum Pathol 40:156-65. 2009
    ..In the future, it may also allow the use of the AQUA-based algorithms to quantify the expression of angiogenic biomarkers to either tumor or microvessel area-specific compartments...
  73. ncbi Definition of a direct extracellular interaction between Met and E-cadherin
    Galina Reshetnikova
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell Biol Int 31:366-73. 2007
    ..We suggest that this receptor/cadherin pairing may be a mechanism for cellular presentation of receptors in a manner that localizes them optimally for interaction with ligand...
  74. ncbi Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells
    Allison W Welsh
    Department of Pathology, BML 116, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT, USA
    J Clin Oncol 29:2978-84. 2011
    ..Here we define a new method for standardization of ER measurement and then examine both change in percentage and threshold of intensity (immunoreactivity) to assess sources for test discordance...
  75. ncbi Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 12:3856-63. 2006
    ..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi...
  76. ncbi Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction
    Aaron J Berger
    Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, USA
    Cancer Res 65:11185-92. 2005
    ..001). We show that a high level of AP-2 expression in the cytoplasm relative to the nucleus correlates with poor prognosis and the loss of nuclear AP-2 expression is associated with malignant transformation and progression of melanoma...
  77. ncbi Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study
    Xiaohong R Yang
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892 7236, USA
    Cancer Res 67:10608-17. 2007
    ....
  78. ncbi Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray
    Gina G Chung
    Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 310 Cedar St, New Haven, CT 06510, USA
    Clin Colorectal Cancer 1:237-42. 2002
    ..Subjective assessment of expression is highly dependent on the method of visualization and may illustrate why discrepant data is often seen in literature based on immunohistochemistry...
  79. ncbi What's in a name?
    David L Rimm
    Arch Pathol Lab Med 130:934-5. 2006
  80. ncbi Bimodal population or pathologist artifact?
    David L Rimm
    J Clin Oncol 25:2487-8. 2007
  81. ncbi Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Int J Cancer 121:1079-85. 2007
    ..07) for low PR and HER2 expression vs. OR = 1.78 (95% CI = 1.25-2.55) for high expression (p-heterogeneity = 0.001). PR and HER2 levels in breast cancer vary by BMI, suggesting a heterogeneous etiology for tumors related to these markers...
  82. ncbi Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study
    Wen Xie
    Division of Medical Oncology, Department of Internal Medicine, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Cancer Res 62:497-505. 2002
    ..Finally, analysis of a small cohort of hereditary breast cancers failed to reveal any association between BRCA1 or BRCA2 genotype and alterations in Smad signaling...
  83. ncbi Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model
    Sharon Pozner Moulis
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Lab Invest 87:251-60. 2007
    ....
  84. ncbi Construction and validation of tissue microarrays of ductal carcinoma in situ and terminal duct lobular units associated with invasive breast carcinoma
    Xiaohong Rose Yang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20852, USA
    Diagn Mol Pathol 15:157-61. 2006
    ..Additional exploration of this approach is needed...
  85. ncbi Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
    ..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression...
  86. ncbi Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites
    Elayne Provost
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA
    J Biol Chem 278:31781-9. 2003
    ..We conclude that these sites may represent an alternative (non-wnt) signaling pathway, which may be inappropriately activated in tumors with mutations of these residues...
  87. ncbi Long-term preservation of antigenicity on tissue microarrays
    Kyle A Divito
    Department of Pathology, Yale University, New Haven, CT, USA
    Lab Invest 84:1071-8. 2004
    ..The use of either paraffin coating or nitrogen storage alone protected slides to a lesser degree...
  88. ncbi Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis
    Wen Xie
    Division of Medical Oncology, Department of Internal Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Cancer J 9:302-12. 2003
    ..This subset has a poor prognosis because of its association with advanced disease and the presence of lymph node metastases at diagnosis...
  89. ncbi Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density
    Sharon Pozner-Moulis
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cancer Res 66:7976-82. 2006
    ..This work suggests processing of the Met receptor, analogous to ErbB4, resulting in the release of the cytoplasmic domain and its translocation to the nucleus in cells at low density...
  90. ncbi Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome
    Maciej P Zerkowski
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Invest 25:19-26. 2007
    ....
  91. ncbi Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  92. ncbi alphaB-crystallin as a marker of lymph node involvement in breast carcinoma
    Dina Chelouche-Lev
    Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2543-8. 2004
    ....
  93. ncbi Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression
    Sujun Hua
    Joint Institute for Genomics and Systems Biology, The University of Chicago and Argonne National Laboratory, Chicago, IL, USA
    Mol Syst Biol 4:188. 2008
    ..This integrated approach has accelerated the identification of a molecule linked to breast cancer progression, has implications for diagnostic and therapeutic interventions, and can be applied to a wide range of cancers...
  94. ncbi Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma
    Gretchen M Kreizenbeck
    Department of Pathology and Public Health, Yale University School of Medicine, New Haven, CT 06520 8034, USA
    Cancer Epidemiol Biomarkers Prev 17:949-58. 2008
    ..Proteins that mediate the epithelial-mesenchymal transition, the process by which a cancer cell disengages from its parent tumor, are important candidates...
  95. ncbi Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens
    Linda M Ernst
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer 96:275-9. 2002
    ..The results of the current study quantitatively confirm the impression of practicing cytopathologists, but also suggest that FNA will provide a good substrate for cDNA microarray and other molecular analyses...

Research Grants16

  1. Optimal Predictors of Response to Trastuzumab
    DAVID L contact RIMM; Fiscal Year: 2010
    ..Validation of the models will be done by Leave One Out Cross Validation methods in anticipation of future more robust validation in an independent cohort in a subsequent study. ..
  2. Predicting Metastasis in Melanoma
    David Rimm; Fiscal Year: 2009
    ..We anticipate this method could provide a future replacement for sentinel node biopsy that is both less morbid and more accurate. ..
  3. Prediction of Breast Cancer Response to Hormonal Thearpy
    David Rimm; Fiscal Year: 2007
    ..abstract_text> ..
  4. Predicting Metastasis to Lymph Nodes
    David Rimm; Fiscal Year: 2007
    ....
  5. Predicting Metastasis in Melanoma
    David Rimm; Fiscal Year: 2007
    ..We anticipate this method could provide a future replacement for sentinel node biopsy that is both less morbid and more accurate. ..
  6. AQUA: A New Quantitative in situ Proteomic Assay
    David Rimm; Fiscal Year: 2004
    ....
  7. ESTABLISHMENT AND REGULATION OF CELL/CELL ADHESION
    David Rimm; Fiscal Year: 2002
    ..We use this tool throughout this proposal in in vitro adhesion assays and also as a unique probe for the homotypic interaction, as a mechanism to assess the co-precipitable components in the adhesion complex. ..
  8. Predicting Metastasis in Melanoma
    David L Rimm; Fiscal Year: 2010
    ....